← All trials
NCT05975580
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2023
- Primary completion
- Apr 2, 2027
- Completion date
- Jul 31, 2027
- First posted
- Aug 4, 2023
- Last posted
- Sep 1, 2023
- Enrollment
- 120
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, IrvineLead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- University of California, IrvineOverall official - principal investigator
- University of California, IrvineReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.